135 related articles for article (PubMed ID: 7940973)
21. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus infection in organ transplant recipients.
Hibberd PL; Snydman DR
Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
[TBL] [Abstract][Full Text] [Related]
23. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
Tenschert W; Gonnermann D; Meyer-Moldenhauer WH; Cremaschi L; Huland H
Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
[No Abstract] [Full Text] [Related]
24. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.
Singh N
Clin Infect Dis; 2005 Mar; 40(5):704-8. PubMed ID: 15714416
[No Abstract] [Full Text] [Related]
25. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
26. A cytomegalovirus vaccine tames the troll of transplantation.
Schleiss MR
Lancet; 2011 Apr; 377(9773):1216-8. PubMed ID: 21481691
[No Abstract] [Full Text] [Related]
27. Cytomegalovirus infections in transplant patients.
Ljungman P
Scand J Infect Dis Suppl; 1996; 100():59-63. PubMed ID: 8860355
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus antigenemia as a marker for antiviral therapy after heart transplantation.
Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayr T; Prenner G; Hipmair G; Grasser B; Freigassner M
J Heart Lung Transplant; 1996 Mar; 15(3):314-5. PubMed ID: 8777216
[No Abstract] [Full Text] [Related]
29. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
30. Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients.
Danziger-Isakov LA; Storch GA
Pediatr Infect Dis J; 2002 May; 21(5):432-4. PubMed ID: 12150182
[No Abstract] [Full Text] [Related]
31. [Organ transplantation infection and its prevention and treatment].
Wang E; Liu Y
Zhonghua Nei Ke Za Zhi; 1996 May; 35(5):350-2. PubMed ID: 9387619
[No Abstract] [Full Text] [Related]
32. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
33. A cytomegalovirus vaccine for transplantation: are we closer?
Go V; Pollard RB
J Infect Dis; 2008 Jun; 197(12):1631-3. PubMed ID: 18444884
[No Abstract] [Full Text] [Related]
34. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD
Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
[TBL] [Abstract][Full Text] [Related]
35. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
36. Optimization of outcomes related to cytomegalovirus in organ transplant recipients.
Singh N
Transplantation; 2006 Jul; 82(1):15-6. PubMed ID: 16861935
[No Abstract] [Full Text] [Related]
37. Cytomegalovirus infection.
Ljungman P; Einsele H
Curr Opin Hematol; 1994 Nov; 1(6):418-22. PubMed ID: 9371316
[TBL] [Abstract][Full Text] [Related]
38. [Diagnosis and treatment of cytomegaloviral chorioretinitis].
Aznabaev MT; Mal'khanov VB; Mambetkulova GK; Ishberdina lSh
Vestn Oftalmol; 2004; 120(6):41-3. PubMed ID: 15678675
[No Abstract] [Full Text] [Related]
39. Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients.
Green M; Michaels M
Pediatr Infect Dis J; 2000 Sep; 19(9):875-7. PubMed ID: 11001112
[No Abstract] [Full Text] [Related]
40. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
